3rd Annual MSL Best Practices Summit, December 4-5, Virtual Event, Expanding the MSL Role and Responsibilities While Core Values Are Maintained to Generate Value in a Compliant and Effective Manner to Better Serve Thought Leaders and Internal Stakeholders

2022 Agenda

Charlie Cook
Sr. Director, Women’s Health and Metabolism Field Medical Team
PFIZER
  • Emotional intelligence and the soft skills needed to thrive as an MSL
  • Career goals and aspirations that match your company and your team
  • Salary expectations for new MSLs with no experience
Naila Inam
Senior Manager, Medical Science Liaisons, Hematology-Oncology
AMGEN

Kasmin Delgado
Associate Director MSLs

Giovani Passiatore
Head of US Medical Science Liaisons ‑ Rare Diseases
CHIESI USA
  • Understanding the role in different companies, the amount of “hats” you need to wear in a small company vs a big company
  • Thinking of transitioning from big pharma to small as an MSL or vice versa? Things you need to consider
  • Ever Changing role, with endless learning curves and tasks – differences and nuances within the different companies
Moderator:
Angela Tom
National Director, US Field Medical Affairs
ORCHARD THERAPEUTICS

Panelists:

Tracey Jason
Head, Medical Affairs, Canada
AMYLYX PHARMACEUTICALS

Dawn Koselleck
Director, Scientific Communications Ophthalmology Medical Affairs
REGENERON PHARMACEUTICALS

Kelley Dacus 
Senior Director Medical Affairs 
RECORDATI RARE DISEASES

Merideth Rodgers
Medical Director
REGENERON PHARMACEUTICALS
Whilst omnichannel was initiated for commercial purposes, increasingly it is being embraced as a cross-functional best practice for effective insights-led engagement with healthcare professionals. As the demands on medical teams increase, we will explore how the MSL fits into this evolving picture and how they can maximize the impact of the engagement, whilst retaining the quality and depth of their stakeholder relationships.

Jessica Ingram 
Executive Vice President and Global Client Partner
OPEN HEALTH

Rosie Humphreys 
Director Technology Solutions
OPEN HEALTH
Interactive Discussions on Relevant Topics – Guided Conversations Prompted by Videos

  • Engage with fellow virtual participants
  • Discuss relevant topics, common challenges and best practices
  • Discover a new and fun way to connect with like-minded peers
Sandy Donaldson
CEO and Co-Founder
IMPIRICUS

Dr. Osama Hashmi
Chief Product Office
IMPIRICUS
  • Quality vs Quantity – focus on valuable interactions and not in the number of them
  • Identify what counts as a successful interaction, a text message, a call back, etc.
  • Apply different performance indicators depending on the medical specialty you work with
Brittany Cross
Director of Operational Excellence, Global Medical Affairs Excellence
KYOWA KIRIN

Christy Smith
Associate Director, NA Oncology MSL Team
KYOWA KIRIN

Andrew Hewitson
EMEA MSL Director
KYOWA KIRIN
  • Help to change the mindset of management so they rally and support MA initiatives that derive in better insight from HCPs and better results for patients
  • Show management where the real value of MSLs is and how they can measure it, not using the same metrics applied for other internal departments
Kathryn Nichol
Vice President, Clinical and Medical Affairs
LIVANOVA
  • Mastering the hybrid engagement, congresses, advisory boards
  • Expanding towards social media for compliant outreach with KOLs
  • New functions on the horizon? Discuss potential new scenarios for MSLs now that KOL access is more complicated than ever before
Moderator:
Tom Caravela
Managing Partner
THE CAROLAN GROUP

Panelists:

Caroline Ojaimi
Head of Global Publications – Oncology
TAKEDA

Elaine Nadeau
Senior Director, Head of US Field Medical Affairs and Medical Excellence
SOBI

Carrie Carretta
Executive Director, Therapeutic Area Head, CNS & Retina, Clinical Development and Medical Affairs
BOEHRINGER INGELHEIM

Charlie Cook
Sr. Director, Women’s Health and Metabolism Field Medical Team
PFIZER
Charlie Cook
Sr. Director, Women’s Health and Metabolism Field Medical Team
PFIZER
  • Framing what does an MSL do pre-launch, around launch, post-launch and why
  • Discussing how the MSL roles, responsibilities and activities change as part of the Life Cycle Management (LCM)
  • Pre-launch or post-launch setting for MSLs? – the value for the Company and the individual MSL
Maja Beilmann-Schramm
Director Global Field Medical Excellence and HCP Exchange
MERCK

Pinky Dharmshaktu 
Global Associate Director, Field Medical Excellence and HCP Exchange
MERCK

Jill Fenwick
Director Global Field Medical Excellence and HCP Exchange
EMD SERONO
  • Employ soft skills and emotional intelligence to be assertive and respectful of the KOLs time
  • Manage and personalize the KOL relationships to deliver quality engagement
  • Help reduce burnout by being specific and concise in your outreach while being flexible and understanding
Chirag Bhagat
Director, Field Medical Affairs & Operations
BLUEBIRD BIO
  • Listen and engage your KOLs on their turf, show flexibility and let them feel acknowledge and cared for
  • Analyze pros and cons of each way to determine which is the most effective for you and your KOLs
  • Learn best practices on each of the 3 ways to excel at your preferred option
Howard Berkowitz
Senior Medical Science Liaison, Respiratory & Immunology, NY Metro Region – US Field-Based Medical Affairs
SANOFI
  • Think outside the slides! KOLs are very interested in tidbits and nuggets of info they can easily access
  • Quick video, an interesting read, an article, a clubhouse recording. Everything related to their expertise field that will captivate them and will set you up for success
  • Use social media to your advantage and share with them on LinkedIn, Twitter, Youtube etc.
Katie Reyes
Medical Communications Specialist
PHASEBIO PHARMACEUTICALS
  • Balance an engaging and communicative relationship with your fellow MSLs to stay updated on what trends and ways to interact with KOLs
  • Delineate the TLL-MSL relationship to showcase a strong team and ensure a complete experience for the KOLs working with your team
  • Compliant organization between Medical and Commercial
Howard Dorfman
Adjunct Professor
SETON HALL UNIVERSITY
  • Use the platforms to learn more about your KOLs and DOLs, what they follow, their interests, this way you can break the noise and provide meaningful interactions
  • Proceed with caution, learn what you should do and do not to avoid scrutiny in your social media engagement
Alyssa Vaysman
Medical Science Liaison
LEO PHARMA

Nayanica Banerjee
Senior Manager, Client Solutions/ Strategy
H1
  • How to work with clinical when they think Medical Affairs ‘slows them down’
  • Try to get your MSLs involved before phase 3 on clinical trials and see the benefits
  • Fantastic opportunity to show the MSL value while working clinical trials
Lauren DeRienzo
Associate Director, Global Medical Affairs
XENON PHARMACEUTICALS

Andrew Shim
Executive Director, Head of Global HEOR/RWE, Global Medical Affairs
TURNING POINT THERAPEUTICS
Romik Ghosh
Director Medical Affairs and Medical Education
NOVO NORDISK